Contraception in Neurologic and Psychiatric Disorders

  • Caryn DuttonEmail author
  • Andrea Hsu Roe
  • Deborah Bartz


All women of reproductive age with psychiatric and neurologic disease should be screened for contraceptive need, and offered counseling on options compatible with their medications and medical conditions. While non-hormonal methods are appropriate for all patients, hormonal contraception may interact with some medications used by women in treatment of epilepsy, multiple sclerosis and mood disorders. Women at risk for or with a history of stroke should avoid estrogen-containing options; similarly, women who report migraine with aura are also discouraged from use of any estrogen-based contraception due to the potential increase in risk of stroke. Fortunately, the highly effective reversible contraceptive options that include intrauterine devices (IUDs) and the progestin-only implant are appropriate for almost all these women. This chapter provides evidence and guidance for selection of appropriate, safe contraceptive options in women with migraine disease, epilepsy, stroke, multiple sclerosis and psychiatric disease.


Contraception Epilepsy Depression Migraine headache Multiple sclerosis Stroke 


  1. 1.
    Trussell J. Contraceptive failure in the United States. Contraception. 2011;83:397–404.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Curtis K, Peipert J. Long-acting reversible contraception. N Engl J Med. 2017;376:461–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Curtis K, Tepper N, Jatlaoui T, Berry-Bibee E, Horton L, Zapata L, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65:1–104.Google Scholar
  4. 4.
    Lipton R, Bigal M. Migraine: epidemiology, impact, and risk factors for progression. Headache. 2005;45:S3–S13.PubMedCrossRefGoogle Scholar
  5. 5.
    Buse D, Manack A, Fanning K, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52:1456–70.CrossRefGoogle Scholar
  6. 6.
    Faubion S, Casey P, Shuster L. Hormonal contraception and migraine: clinical considerations. Curr Pain Headache Rep. 2012;16:461–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Daniels K, Daugherty J, Jones J, Mosher W. Current contraceptive use and variation by selected characteristics among women aged 15–44: United States, 2011–2013. Natl Health Stat Rep. 2015;86:1–14.Google Scholar
  8. 8.
    Etminan M, Takkouche B, Isorna F, Samii A. Risks of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ. 2005;330:63.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Tepper N, Whiteman M, Zapata L, Marchbanks P, Curtis K. Safety of hormonal contraceptives among women with migraine: a systematic review. Contraception. 2016;94:630–40.PubMedCrossRefGoogle Scholar
  10. 10.
    Fazio G, Ferrara F, Barbaro G, Alessandro G, Ferrro G, Novo G, et al. Prothrombotic effects of contraceptives. Curr Pharm Des. 2010;16:3490–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Bousser M, Conard J, Kittner S, de Lignieres B, MacGregor E, Massiou H, et al. Recommendations of the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. The International Headache Society Task Force on Combined Oral Contraceptives & Hormone Replacement Therapy. Cephalalgia. 2000;20:155–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Lidegaard O, Lokkegaard E, Jensen A, Skovlund C, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366:2257–66.PubMedCrossRefGoogle Scholar
  13. 13.
    Champaloux S, Tepper N, Monsour M, Curtis K, Whiteman M, Marchbanks P, et al. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. Am J Obstet Gynecol. 2017;216:489.e1–7.CrossRefGoogle Scholar
  14. 14.
    Russell M, Rasmussen B, Fenger K, Olesen J. Migraine without aura and migraine with aura are distinct clinical entities: a study of four hundred and eight-four male and female migraineurs from the general population. Cephalalgia. 1996;16:239–45.CrossRefGoogle Scholar
  15. 15.
    Kurth T, Chabriat H, Bousser M. Migraine and stroke: a complex association with clinical implications. Lancet Neurol. 2012;11:92–100.CrossRefGoogle Scholar
  16. 16.
    Tepper N, Whiteman M, Marchbanks P, James A, Curtis K. Progestin-only contraception and thromboembolism: a systematic review. Contraception. 2016;94:678–700.PubMedCrossRefGoogle Scholar
  17. 17.
    Rosenberg M, Waugh M. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol. 1998;179:577–82.PubMedCrossRefGoogle Scholar
  18. 18.
    Loder E, Buse D, Golub J. Headache and combination estrogen-progestin oral contraceptives: integrating evidence, guidelines, and clinical practice. Headache. 2005;45:224–31.PubMedCrossRefGoogle Scholar
  19. 19.
    Berger G, Edelman D, Talwar P. The probability of side effects with ovral, norinyl 1/50 and norlestrin. Contraception. 1979;20:447–53.PubMedCrossRefGoogle Scholar
  20. 20.
    Martin V, Behbehani M. Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis—part 1. Headache. 2006;46:3–23.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Loder E, Rizzoli P, Golub J. Hormonal management of migraine associated with menses and the menopause: a clinical review. Headache. 2007;47:329–40.PubMedCrossRefGoogle Scholar
  22. 22.
    MacGregor A. Migraine associated with menstruation. Funct Neurol. 2000;15:143–5.PubMedGoogle Scholar
  23. 23.
    Hatcher R, Trussell J, Nelson A, Cates W, Kowal D, Policar M. Contraceptive technology. 20th ed. Atlanta: Bridging the Gap Communications; 2011.Google Scholar
  24. 24.
    Calhoun A, Ford S, Pruitt A. The impact of extended-cycle vaginal ring contraception on migraine aura: a retrospective case series. Headache. 2012;52:1246–53.CrossRefGoogle Scholar
  25. 25.
    Larsson-Cohn U, Lundberg P. Headache and treatment with oral contraceptives. Acta Neurol Scand. 1970;46:267–78.CrossRefGoogle Scholar
  26. 26.
    De Leo V, Scolaro V, Musacchio M, Di Sabatino A, Morgante G, Cianci A. Combined oral contraceptives in women with menstrual migraine without aura. Fertil Steril. 2011;96:917–20.CrossRefGoogle Scholar
  27. 27.
    Sulak P, Willis S, Kuehl T, Coffee A, Clark J. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache. 2007;47:27–37.Google Scholar
  28. 28.
    Harden C, Pennell P. Neuroendocrine considerations in the treatment of men and women with epilepsy. Lancet Neurol. 2013;12:72–83.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Pennell P, Davis A. Selecting contraception for women treated with antiepileptic drugs. In: Klein A, Angela O’Neal M, Scifres C, Waters JFR, Waters JH, editors. Neurological illness in pregnancy: principles and practice. 1st ed: Wiley; 2016. p. 110–21.Google Scholar
  30. 30.
    Vessey M, Painter R, Yeates D. Oral contraception and epilepsy: findings in a large cohort study. Contraception. 2002;66:77–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Harden C, Leppik I. Optimizing therapy of seizures in women who use oral contraceptives. Neurology. 2006;67:s56–8.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Herzog A, Mandle H, Cahill K, Fowler K, Houser W. Differential impact of contraceptive methods on seizures varies by anti-epileptic drug category: findings of the epilepsy birth control registry. Epilepsy Behav. 2016;60:112–7.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Davis A, Saadatmand H, Pack A. Women with epilepsy initiating a progestin IUD: a prospective pilot study of safety and acceptability. Epilepsia. 2016;57:1143–8.Google Scholar
  34. 34.
    Dutton C, Foldvary-Shafer N. Contraception in women with epilepsy: pharmacokinetic interactions, contraceptive options and management. Int Rev Neurobiol. 2008;83:113–34.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Davis A, Westhoff C, Stanczyk F. Carbamazepine co-administration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation and bleeding. Epilepsia. 2011;52:243–7.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Lazorwitz A, Swartz M, Davis A, Guihai M. The effect of carbamazepine on etonogestrel concentrations among contraceptive implant users. Contraception. 2016;94:571–7.CrossRefGoogle Scholar
  37. 37.
    Curtis K, Tepper N, Jatlaoui T, Berry-Bibee E, Horton L, Zapata L, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65:48.Google Scholar
  38. 38.
    U.S. Food and Drug Administration. FDA Drug Safety Communication: updated information about the risk of blood clots in women taking brith control pills containing drospirenone. 2011. Available from:
  39. 39.
    World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives: Results of an international, multicenter, case-control study. Contraception. 1998;57:315–24.CrossRefGoogle Scholar
  40. 40.
    Heinemann L, Assmann A, DoMinh T, Garb E. Oral progestogen only contraceptives and cardiovascular risk: results from the transnational study on oral contraceptives and the health of young women. Eur J Contracept Reprod Health Care. 1999;4:67–73.PubMedCrossRefGoogle Scholar
  41. 41.
    Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet. 1999;354:1610–1.PubMedCrossRefGoogle Scholar
  42. 42.
    Bergendal A, Persson I, Odeberg J, Sundstrom A, Holmstrom M, Schulman S, et al. Obstet Gynecol. 2014;124:600–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Mantha S, Karp R, Raghavan V, Terrin N, Bauer K, Zwicker J. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ. 2012;345:e4944.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Bove R, Alwan S, Friedman J, Hellwig K, Houtchens M, Koren G, et al. Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. Obstet Gynecol. 2014;124:1157–68.PubMedCrossRefGoogle Scholar
  45. 45.
    Houtchens M, Kolb C. Multiple sclerosis and pregnancy: therapeutic considerations. J Neurol. 2013;260:1202–4.PubMedCrossRefGoogle Scholar
  46. 46.
    Fragoso Y, Adoni T, Alves-Leon S, Azambuja NJ, Barreira A, Brooks J, et al. Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review. CNS Drugs. 2013;27:955–61.PubMedCrossRefGoogle Scholar
  47. 47.
    Sahin L, Nallani S, Tassinari M. Medication use in pregnancy and the pregnancy and lactation labeling rule. Clin Pharmacol Ther. 2016;100:23–5.PubMedCrossRefGoogle Scholar
  48. 48.
    Vukusic S, Marignier R. Multiple sclerosis and pregnancy in the ‘treatment era. Nat Rev Neurol. 2015;11:280–9.CrossRefGoogle Scholar
  49. 49.
    David O, Ocwieja M, Meise K, Emotte C, Jakab A, Wemer J, et al. Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results. Int J Clin Pharmacol Ther. 2012;50:540–4.PubMedCrossRefGoogle Scholar
  50. 50.
    Villard-Mackintosh L, Vessey M. Oral contraceptives and reproductive factors in multiple sclerosis incidence. Contraception. 1993;47:161–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Thorogood M, Hannaford P. The influence of oral contraceptives on the risk of multiple sclerosis. Br J Obstet Gynecol. 1998;105:1296–9.CrossRefGoogle Scholar
  52. 52.
    Zapata L, Oduyebo T, Whiteman M, Houtchens M, Marchbanks P, Curtis K. Contraceptive use among women with multiple sclerosis: a systematic review. Contraception. 2016;94:612–20.PubMedCrossRefGoogle Scholar
  53. 53.
    Kempe P, Hammar M, Brynhildsen J. Symptoms of multiple sclerosis during use of combined hormonal contraception. Eur J Obstet Gynecol Reprod Biol. 2015;19:1–4.CrossRefGoogle Scholar
  54. 54.
    Westhoff C, Heartwell S, Edwards S, Zieman M, Stuart G, Cwiak C, et al. Oral contraceptive discontinuation: do side effects matter? Am J Obstet Gynecol. 2007;196:412.e1–7.CrossRefGoogle Scholar
  55. 55.
    Parry B, Rush A. Oral contraceptives and depressive symptomatology: biologic mechanisms. Compr Psychiatry. 1979;20:347–58.PubMedCrossRefGoogle Scholar
  56. 56.
    Herzberg B, Johnson A, Brown S. Depressive symptoms and oral contraceptives. Br Med J. 1970;4:142–5.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Pagano H, Zapata L, Berry-Bibee E, Nanda K, Curtis K. Safety of hormonal contraception and intrauterine devices among women with depressive and bipolar disorders: a systematic review. Contraception. 2016;94(6):641–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Keyes K, Cheslack-Postava K, Westhoff C, Heim C, Haloossim M, Walsh K, et al. Association of hormonal contraceptive use with reduced levels of depressive symptoms: a national study of sexually active women in the United States. Am J Epidemiol. 2013;178:1378–88.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Skovlund C, Morch L, Kessing L, Lidegaard O. Association of hormonal contraception with depression. JAMA Psychiat. 2016;73:1154–62.CrossRefGoogle Scholar
  60. 60.
    Skovlund C, Morch L, Kessing L, Lange T, Lidegaard O. Association of hormonal contraception with suicide attempts and suicides. AJP Adv. 2017.
  61. 61.
    O’Connell K, Davis A, Kerns J. Oral contraceptives: side effects and depression in adolescent girls. Contraception. 2007;75:299–304.PubMedCrossRefGoogle Scholar
  62. 62.
    Duke J, Sibbritt D, Young A. Is there an association between the use of oral contraception and depressive symptoms in young Australian women? Contraception. 2007;75:27–31.PubMedCrossRefGoogle Scholar
  63. 63.
    Herzberg B, Draper K, Johnson A, Nicol G. Oral contraceptives, depression, and libido. Br Med J. 1971;3:495–500.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Joffe H, Cohen L, Harlow B. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol. 2003;189:1523–30.PubMedCrossRefGoogle Scholar
  65. 65.
    Segebladh B, Borgstrom A, Odlind V, Bixo M, Sundstrom-Poromaa I. Prevalence of psychiatric disorders and premenstrual dysphoric symptoms in patients with experience of adverse mood during treatment with combined oral contraceptives. Contraception. 2009;79:50–5.PubMedCrossRefGoogle Scholar
  66. 66.
    Bergstrom R, Goldberg M, Cerimele B, Hatcher B. Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. Clin Pharmacol Ther. 1997;62:643–51.PubMedCrossRefGoogle Scholar
  67. 67.
    Chen G, Lee R, Hojer A, Buchbjerg J, Serenko M, Zhao Z. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig. 2013;33:727–36.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Koke S, Brown E, Miner C. Safety and efficacy of fluoxetine in patients who receive oral contraceptive therapy. Obstet Gynecol. 2002;187:551–5.Google Scholar
  69. 69.
    Kornstein S, Toups M, Rush A, Wisniewski S, Thase M, Luther J, et al. Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the sequenced treatment alternatives to relieve depression (STAR*D) study. J Women's Health. 2013;22:121–31.CrossRefGoogle Scholar
  70. 70.
    Beaumont G. Drug interactions with clomipramine (Anafranil). J Int Med Res. 1973;1:480–4.CrossRefGoogle Scholar
  71. 71.
    Gringras M, Beaumont G, Grieve A. Clomipramine and oral contraceptives: an interaction study–clinical findings. J Int Med Res. 1980;8:76–80.PubMedGoogle Scholar
  72. 72.
    Abernethy D, Greenblatt D, Shader R. Imipramine disposition in users of oral contraceptive steroids. Clin Pharmacol Ther. 1984;35:792–7.PubMedCrossRefGoogle Scholar
  73. 73.
    Edelbroek P, Zitman F, Knoppert-van der Klein E, van Putten P, de Wolff F. Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women. Clin Chim Acta. 1987;165:177–87.PubMedCrossRefGoogle Scholar
  74. 74.
    Berry-Bibee E, Kim M, Simmons K, Tepper N, Riley H, Pagano H, et al. Drug interactions between hormonal contraceptives and psychotropic drugs: a systematic review. Contraception. 2016;94:650–67.PubMedCrossRefGoogle Scholar
  75. 75.
    Palovaara S, Pelkonen O, Uusitalo J, Lundgren S, Laine K. Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2003;74:326–33.CrossRefGoogle Scholar
  76. 76.
    Edelman A, Micks E, Gallo M, Jensen J, Grimes D. Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst Rev. 2014;7:CD004695.Google Scholar
  77. 77.
    Lopez L, Kaptein A, Helmerhorst F. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2012;2:CD006586.Google Scholar
  78. 78.
    Freeman E, Halbreich U, Grubb G, Rapkin A, Skouby S, Smith L, et al. An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome. Contraception. 2012;85(5):437–45.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Berenson A, Asem H, Tan A, Wilkinson G. Continuation rates and complications of intrauterine contraception in women diagnosed with bipolar disorder. Obstet Gynecol. 2011;118:1331–6.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Rasgon N, Bauer M, Glenn T, Elman S, Whybrow P. Menstrual cycle related mood changes in women with bipolar disorder. Bipolar Disord. 2003;5:48–52.PubMedCrossRefGoogle Scholar
  81. 81.
    Chiu Y, Ereshefsky L, Preskorn S, Poola N, Loebel A. Lurasidone drug–drug interaction studies: a comprehensive review. Drug Metabol Drug Interact. 2014;29:191–202.PubMedCrossRefGoogle Scholar
  82. 82.
    Muirhead G, Harness J, Holt P, Oliver S, Anziano R. Ziprasidone and the pharmacokinetics of a combined oral contraceptive. Clin Pharmacol. 2000;49:49S–56S.CrossRefGoogle Scholar
  83. 83.
    Haslemo T, Refsum H, Molden E. The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine. Clin Pharmacol. 2011;71:611–6155.CrossRefGoogle Scholar
  84. 84.
    Garbers S, Correa N, Tobier N, Blust S, Chiasson M. Association between symptoms of depression and contraceptive method choices among low-income women at urban reproductive health centers. Matern Child Health J. 2010;14:102–9.PubMedCrossRefGoogle Scholar
  85. 85.
    Hall K, White K, Rickert V, Reame N, Westhoff C. Influence of depressed mood and psychological stress symptoms on perceived oral contraceptive side effects and discontinuation in young minority women. Contraception. 2012;86:518–25.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Callegari L, Zhao X, Nelson K, Borerro S. Contraceptive adherence among women veterans with mental illness and substance use disorder. Contraception. 2015;91:386–92.PubMedCrossRefGoogle Scholar
  87. 87.
    American College of Obstetricians and Gynecologists. Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. ACOG Committee Opinion No. 450. Obstet Gynecol. 2009;14:1434–8.Google Scholar
  88. 88.
    Ott M, Sucato G. Contraception for adolescents. Pediatrics. 2014;134:e1244–5.CrossRefGoogle Scholar
  89. 89.
    Davis A, Pack A, Dennis A. Contraception for women with epilepsy. In: Allen RH, Cwiak C, editors. Contraception for the medically challenging patient. New York: Springer Science+Business Media; 2014.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Caryn Dutton
    • 1
    • 2
    Email author
  • Andrea Hsu Roe
    • 3
    • 4
  • Deborah Bartz
    • 1
    • 2
  1. 1.Department of Obstetrics and GynecologyBrigham and Women’s HospitalBostonUSA
  2. 2.Harvard Medical SchoolBostonUSA
  3. 3.Department of Obstetrics and GynecologyHospital of the University of PennsylvaniaPhiladelphiaUSA
  4. 4.Perelman School of Medicine, University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations